{
    "clinical_study": {
        "@rank": "90808", 
        "arm_group": {
            "arm_group_label": "DCDS4501A", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, open-label, dose-escalation study will evaluate the safety and anti-tumor\n      activity of DCDS4501A in combination with rituximab, cyclophosphamid e, doxorubicin and\n      prednisone in patients with non-Hodgkin's lymphoma. Cohort of patients will receive\n      escalating doses of DCDS4501A intravenously every 3 weeks in combination with standard doses\n      of rituximab, cyclophosphamide, doxorubicin and oral prednisone. Patients will be treated\n      for a total of six or eight cycles in accordance with local institutional practice."
        }, 
        "brief_title": "A Study of DCDS4501A in Combination With Rituximab, Cyclophosphamide, Doxorubicin and Prednisone in Patients With B-Cell Non-Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphoma, B-Cell, Non-Hodgkin's Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All Patients:\n\n          -  Adult patients, 60 to 80 years of age, inclusive\n\n          -  At least one bi-dimensionally measurable lesion, defined as > 1.5 cm in its longest\n             dimension\n\n          -  Life expectancy of at least 24 weeks\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n\n          -  Adequate hematologic function (unless inadequate function is due to underlying\n             disease, as established by extensive bone marrow involvement or is due to\n             hypersplenism secondary to the involvement of the spleen by lymphoma per the\n             investigator)\n\n        Dose-Escalation Portion of the Study:\n\n          -  Histologically confirmed B-cell NHL: Patients with newly diagnosed B-cell\n             non-Hodgkin's lymphoma (NHL) or relapsed/refractory B-cell NHL are eligible\n\n          -  No more than one prior systemic treatment regimen for B-cell NHL (single agent\n             anti-CD20 monoclonal antibody therapy will not be counted as a prior treatment\n             regimen)\n\n          -  No prior treatment with anthracyclines\n\n        Expansion Portion of the Study:\n\n          -  Previously untreated patients with diffuse large B-cell lymphoma (DLBCL)\n\n          -  Age-adjusted IPI score of 2-3\n\n        Exclusion Criteria:\n\n        Dose-Escalation Portion of the Study:\n\n          -  Diagnosis of primary mediastinal DLBCL\n\n        Expansion Portion of the Study:\n\n          -  Patients with transformed lymphoma\n\n          -  Prior therapy for NHL\n\n        All Patients:\n\n          -  Prior stem cell transplant\n\n          -  History of severe allergic or anaphylactic reactions to humanized or murine\n             monoclonal antibodies or known sensitivity or allergy to murine products\n\n          -  Contraindication to receive any of the individual components of R-CHP\n\n          -  Current Grade > 1 peripheral neuropathy, with the exception of pre-phase treatment\n             with prednisone/prednisolone\n\n          -  Ongoing corticosteroid use of > 30 mg/day of prednisone/prednisolone or equivalent.\n             Patients receiving corticosteroid treatment with </= 30 mg/day of\n             prednisone//prednisolone or equivalent must be documented to be on a stable dose of\n             at least 4 weeks' duration before Cycle 1 Day 1\n\n          -  Primary CNS lymphoma\n\n          -  History of other malignancy that could affect compliance with the protocol or\n             interpretation of results Patients with a history of curatively treated basal or\n             squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix\n             are eligible.\n\n        Patients with a malignancy that has been treated with surgery alone with curative intent\n        will also be excluded unless the malignancy has been in documented remission without\n        treatment for >/= 5 years before enrollment.\n\n          -  Evidence of significant, uncontrolled concomitant diseases, including renal disease\n             that would preclude chemotherapy administration, or pulmonary disease (including\n             obstructive pulmonary disease and history of bronchospasm)\n\n          -  Significant cardiovascular disease (such as New York Heart Association Class III or\n             IV cardiac disease, congestive heart failure, myocardial infarction within the\n             previous 6 months, unstable arrhythmias, or unstable angina)\n\n          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection\n             (excluding fungal infections of nail beds) at study enrollment or any major episode\n             of infection requiring treatment with IV antibiotics or hospitalization (relating to\n             the completion of the course of antibiotics) within 4 weeks before Cycle 1 Day 1\n\n          -  Clinically significant history of liver disease, including viral or other hepatitis,\n             current alcohol abuse, or cirrhosis\n\n          -  Positive for hepatitis B or hepatitis C infection\n\n          -  Prior radiotherapy to the mediastinal/pericardial region\n\n          -  Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992653", 
            "org_study_id": "GO29044"
        }, 
        "intervention": [
            {
                "arm_group_label": "DCDS4501A", 
                "description": "escalating doses IV every 3 weeks, 6 or 8 cycles", 
                "intervention_name": "DCDS4501A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "DCDS4501A", 
                "description": "375 mg/m2 IV every 3 weeks, 6 or 8 cycles", 
                "intervention_name": "rituximab [MabThera/Rituxan]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "DCDS4501A", 
                "description": "750 mg/m2 IV every 3 weeks, 6 or 8 cycles", 
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "DCDS4501A", 
                "description": "100 mg orally daily for five days every 3 weeks, 6 or 8 cycles", 
                "intervention_name": "prednisone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "DCDS4501A", 
                "description": "50 mg/m2 IV every 3 weeks, 6 or 8 cycles", 
                "intervention_name": "doxorubicin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Rituximab", 
                "Doxorubicin", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97477"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "19024"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Creteil", 
                        "country": "France", 
                        "zip": "94010"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pessac", 
                        "country": "France", 
                        "zip": "33604"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pierre Benite", 
                        "country": "France", 
                        "zip": "69495"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35033"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "76038"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE Ib STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF DCDS4501A IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO29044 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 40 weeks"
            }, 
            {
                "measure": "Safety: Incidence of anti-DCDS4501A antibodies", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Dose-limiting toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992653"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed through four cycles of treatment, for an expected average of 12 weeks."
            }, 
            {
                "measure": "Pharmacokinetics: Maximum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed through four cycles of treatment, for an expected average of 12 weeks."
            }, 
            {
                "measure": "Pharmacokinetics: Clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed through four cycles of treatment, for an expected average of 12 weeks."
            }, 
            {
                "measure": "Pharmacokinetics: Terminal half-life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed through four cycles of treatment, for an expected average of 12 weeks."
            }, 
            {
                "measure": "Pharmacokinetics: Steady-state volume of distribution (Vss)", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed through four cycles of treatment, for an expected average of 12 weeks."
            }, 
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Complete response rate", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Event-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}